Allan Buzibye

524 total citations
23 papers, 295 citations indexed

About

Allan Buzibye is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Allan Buzibye has authored 23 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Infectious Diseases, 8 papers in Virology and 7 papers in Epidemiology. Recurrent topics in Allan Buzibye's work include HIV/AIDS drug development and treatment (15 papers), HIV Research and Treatment (8 papers) and HIV/AIDS Research and Interventions (6 papers). Allan Buzibye is often cited by papers focused on HIV/AIDS drug development and treatment (15 papers), HIV Research and Treatment (8 papers) and HIV/AIDS Research and Interventions (6 papers). Allan Buzibye collaborates with scholars based in Uganda, United States and United Kingdom. Allan Buzibye's co-authors include Mohammed Lamorde, Barbara Castelnuovo, Pauline Byakika‐Kibwika, Christine Sekaggya‐Wiltshire, Andrew Kambugu, Jan Fehr, Concepta Merry, Amrei von Braun, David Back and Kimberly K. Scarsi and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Allan Buzibye

20 papers receiving 294 citations

Peers

Allan Buzibye

EPIDE

PPCH

PHEOH

SURGE

Vicente Sperb Antonello Brazil

Hadija Semvua Tanzania

Chhaya Valvi India

Yoninah Cramer United States

Rupa Kanapathipillai France

Oluma Y. Bushen United States

Mary L. Townsend United States

Firdose Nakwa South Africa

Onike Rodrigues Ghana

José Cerbino-Neto Brazil

Vicente Sperb Antonello Brazil

Allan Buzibye

93 ×0.5

110 ×1.2

EPIDE

22 ×0.4

PPCH

36 ×0.6

PHEOH

57 ×1.3

SURGE

Citations per year, relative to Allan Buzibye Allan Buzibye (= 1×) peers Vicente Sperb Antonello

Countries citing papers authored by Allan Buzibye

Since Specialization

Citations

This map shows the geographic impact of Allan Buzibye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan Buzibye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan Buzibye more than expected).

Fields of papers citing papers by Allan Buzibye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allan Buzibye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan Buzibye. The network helps show where Allan Buzibye may publish in the future.

Co-authorship network of co-authors of Allan Buzibye

This figure shows the co-authorship network connecting the top 25 collaborators of Allan Buzibye. A scholar is included among the top collaborators of Allan Buzibye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan Buzibye. Allan Buzibye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laker, Eva, Melanie R. Nicol, Allan Buzibye, et al.. (2025). A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda. HIV Medicine. 26(4). 592–605. 1 indexed citations

Buzibye, Allan, Barbara Castelnuovo, Robert C. Bollinger, et al.. (2025). Dolutegravir-associated hyperglycemia: a narrative review. AIDS Research and Therapy. 22(1). 93–93.

Buzibye, Allan, et al.. (2024). Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother–infant pairs. CPT Pharmacometrics & Systems Pharmacology. 13(11). 1915–1923. 1 indexed citations

Schwarz, Jean‐Marc, Nele Brusselaers, Robert C. Bollinger, et al.. (2024). Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks. BMC Infectious Diseases. 24(1). 746–746.

Musaazi, Joseph, Allan Buzibye, Rob E. Aarnoutse, et al.. (2023). Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin. Antimicrobial Agents and Chemotherapy. 67(11). e0043023–e0043023. 4 indexed citations

Ocan, Moses, et al.. (2023). Pharmacopeial quality of artemether–lumefantrine anti-malarial agents in Uganda. Malaria Journal. 22(1). 165–165. 5 indexed citations

Buzibye, Allan, Richard Kwizera, Pauline Byakika‐Kibwika, et al.. (2023). Building clinical pharmacology laboratory capacity in low- and middle-income countries: Experience from Uganda. African Journal of Laboratory Medicine. 12(1). 1956–1956. 1 indexed citations

Castelnuovo, Barbara, Nele Brusselaers, Robert C. Bollinger, et al.. (2023). Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults. AIDS Research and Therapy. 20(1). 65–65. 3 indexed citations

Buzibye, Allan, Kara Wools‐Kaloustian, Adeniyi Olagunju, et al.. (2023). Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study. AIDS Research and Therapy. 20(1). 20–20.

10.

Musaazi, Joseph, Allan Buzibye, Rob E. Aarnoutse, et al.. (2023). Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin. Antimicrobial Agents and Chemotherapy. 67(11). e0043123–e0043123. 1 indexed citations

11.

Sekaggya‐Wiltshire, Christine, Joseph Musaazi, Allan Buzibye, et al.. (2022). Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin. Clinical Infectious Diseases. 76(3). e910–e919. 14 indexed citations

12.

Cresswell, Fiona V, David B. Meya, Enock Kagimu, et al.. (2021). High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clinical Infectious Diseases. 73(5). 876–884. 45 indexed citations

13.

Tumwine, James, et al.. (2020). Antiretroviral drugs found in pork on Ugandan market: Implications for HIV/AIDS treatment. One Health. 9. 100125–100125. 7 indexed citations

14.

Sekaggya‐Wiltshire, Christine, Maxwell Chirehwa, Joseph Musaazi, et al.. (2019). Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?. Antimicrobial Agents and Chemotherapy. 63(6). 41 indexed citations

15.

Buzibye, Allan, Joseph Musaazi, Amrei von Braun, et al.. (2019). Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study. AIDS Research and Therapy. 16(1). 39–39. 8 indexed citations

16.

Sekaggya‐Wiltshire, Christine, Barbara Castelnuovo, Amrei von Braun, et al.. (2017). Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. BMJ Open. 7(9). e014679–e014679. 8 indexed citations

17.

Sekaggya‐Wiltshire, Christine, Amrei von Braun, Alexandra U. Scherrer, et al.. (2016). Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. Journal of Antimicrobial Chemotherapy. 72(4). dkw534–dkw534. 24 indexed citations

18.

Scarsi, Kimberly K., Kristin M. Darin, David Back, et al.. (2015). Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. Clinical Infectious Diseases. 62(6). 675–682. 67 indexed citations

19.

Sekaggya‐Wiltshire, Christine, Mohammed Lamorde, Alexandra U. Scherrer, et al.. (2014). Low isoniazid and rifampicin concentrations in TB/HIV co‐infected patients in Uganda. Journal of the International AIDS Society. 17(4S3). 19585–19585. 8 indexed citations

20.

Lamorde, Mohammed, Kim Sigaloff, Cissy Kityo, et al.. (2014). Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique. BMC Infectious Diseases. 14(1). 473–473. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact